

## FACSIMILE TRANSMISSION

DATE: November 14, 2002  
TO: Examiner Sonya N. Wright  
FIRM: USPTO  
LOCATION: Washington DC  
NUMBER: 1-703-308-7922  
FROM: **Kenneth F. Mitchell Ph.D., Senior Patent Attorney**  
LOCATION: **AstraZeneca Pharmaceuticals LP, Wilmington**  
NUMBER: **FAX - 302-886-8221**      **Phone - 302-886-7466**

Number of pages including cover sheet: **3**

If you have any questions or problems with this transmission, please call me at 302-886-7466.

### **COMMENTS:**

\*\*\*\*\*  
The information contained in this Fax is intended only for the personal and confidential use of the designated recipient or recipients named above. If you are not the intended recipient or the person responsible for delivering it to the intended recipient or recipients you are hereby notified that you have received this document in error, and that any reading, dissemination, distribution or copying of this document is strictly prohibited. If you have received this communication in error, please notify us immediately by FAX or telephone to the numbers above, and return the original to us. Thank you.

UNOFFICIAL

AstraZeneca Docket No. A2090-1P US

## IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

Application of: **Loch III, et al.**  
 Application Number: **09/529,654**  
 Filed: **February 16, 2001**  
 For: **Novel Arylalkyl Amines of Soprofuropyridines**

**Useful in Therapy**

Group Art Unit: 1626  
 Examiner: **Wright, Sonya N.**


Assistant Commissioner for Patents  
 Washington, DC 20231

INFORMAL SUBMISSION

Dear Examiner Wright:

I have discussed your concerns with the inventors of this application and Claim 1 amended with proviso indicated below would be acceptable.

1.(Amended) A compound of formula I,



wherein

NRR<sub>1</sub> is attached at the 5- or 6-position of the furopyridine ring;R is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, or COR<sub>2</sub>;R<sub>1</sub> is (CH<sub>2</sub>)<sub>n</sub>Ar, CH<sub>2</sub>CH=CHAr, or CH<sub>2</sub>C≡CAr;

n is 0 to 3;

A is N or NO;

AstraZeneca Docket No. A2090-1P US  
Application No. 09/529,654  
Page 2

Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or:

an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; any of which may optionally be substituted with one to two substituents independently selected from: halogen, trifluoromethyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> alkoxy; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, OH, OC<sub>1</sub>-C<sub>4</sub> alkyl, CO<sub>2</sub>R<sub>5</sub>, -CN, -NO<sub>2</sub>, -NR<sub>3</sub>R<sub>4</sub>, or -CF<sub>3</sub>;

R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently hydrogen; C<sub>1</sub>-C<sub>4</sub> alkyl; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, OH, OC<sub>1</sub>-C<sub>4</sub> alkyl, -CN; -NO<sub>2</sub>, or -CF<sub>3</sub>;

with the proviso that when R is hydrogen, R<sup>1</sup> is not phenyl or CH<sub>2</sub>-phenyl;  
or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

Dated: November 14, 2002

Respectfully submitted,

By:

  
Kenneth F. Mitchell, Ph.D.  
Attorney for Applicants  
Reg. No. 42,007  
Telephone: 302/886-7466